NEW YORK, March 28, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of PTC Therapeutics, Inc. (“PTC” or the “Company”) (Nasdaq:PTCT) between May 7, 2014 and February 29, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the District of New Jersey. If you purchased or otherwise acquired PTC securities between May 7, 2014 and February 29, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/ptc-therapeutics.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects.
On February 23, 2016, PTC announced that it received a Refuse to File letter from the United States Food and Drug Administration (“FDA”) regarding the New Drug Application for Translarna. The FDA stated in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review. Then on February 29, 2016, the Company’s CEO acknowledged that, according to the FDA, the Company did not provide substantial scientific evidence of effectiveness as it eliminated “data from a majority of enrolled patients.”
If you suffered a loss in PTC you have until May 2, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/ptc-therapeutics.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 



